Nitisinone
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Nitisinone: From Hereditary Tyrosinemia Type 1 to Renal Tubular Acidosis
One-Sentence Summary
Nitisinone (NTBC) is used to treat hereditary tyrosinemia type 1 (HT1), based on the literature context available in this evidence pack (no official UK indication data is currently on file for this drug). The TxGNN model predicts it may be effective for Renal Tubular Acidosis, with 0 clinical trials and 2 publications currently supporting this direction — both observational studies conducted in HT1 patients rather than an independent RTA population.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in UK regulatory data (drug currently not marketed); literature evidence in this pack consistently identifies hereditary tyrosinemia type 1 (HT1) as the treated condition |
| Predicted New Indication | Renal Tubular Acidosis |
| TxGNN Prediction Score | 99.96% |
| Evidence Level | L3 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed, sourced mechanism-of-action data is not available in the drug-level record (original_moa is a data gap). However, the repurposing rationale supplied alongside the prediction describes the mechanism: Nitisinone inhibits 4-hydroxyphenylpyruvate dioxygenase (HPPD), an early enzyme in the tyrosine degradation pathway. In HT1, this blocks the accumulation of downstream toxic metabolites (including succinylacetone), which are known to damage proximal renal tubular function.
The link to renal tubular acidosis is mechanistically plausible but indirect. Both supporting publications describe improvement in renal tubular dysfunction/RTA as a secondary consequence of treating the underlying HT1 with NTBC — not evidence that Nitisinone treats RTA arising from other, unrelated causes. In other words, the benefit observed so far is disease-specific (HT1-associated RTA), and extrapolation to RTA as a standalone new indication has not been demonstrated.
Given this, the mechanistic reasoning is coherent within the HT1 population but has limited generalisability beyond it, which should be weighed carefully before treating this as a genuinely new indication rather than a recognised complication-resolution effect of existing therapy.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 25172236 | 2014 | Cohort | Molecular Genetics and Metabolism | Early NTBC therapy in HT1 patients was associated with improvement in renal tubular dysfunction, indicating a secondary renal benefit from treating the underlying metabolic disease. |
| 27109516 | 2016 | Case Series | Indian Journal of Gastroenterology | Case series of four children with tyrosinemia treated with NTBC; those remaining on long-term therapy showed normal liver function and no reported renal tubular complications. |
UK Market Information
This drug currently has no recorded marketing authorisations in the UK dataset (market status: not marketed; total licences: 0). No product, dosage form, or approved indication information is available for this candidate at present.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
(Key warnings, contraindications, and drug interaction data are all currently unavailable for this candidate — obtaining the official product label is a blocking gap for further safety assessment; see Next Steps below.)
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence is currently limited to two observational studies (a cohort study and a case series) conducted exclusively in HT1 patients, where RTA improvement was a secondary effect of treating the primary disease rather than evidence of an independent indication. There are no clinical trials, and a blocking safety data gap (missing product warnings/contraindications) prevents even a preliminary safety assessment.
To proceed, the following is needed:
- Official UK product label / SmPC (warnings and contraindications) to close the blocking safety data gap
- Confirmed, sourced mechanism-of-action documentation (currently a data gap)
- Evidence distinguishing whether RTA responds to Nitisinone independently of HT1, or only as a downstream effect of correcting the primary metabolic defect
- If mechanistic independence cannot be established, this candidate should not progress beyond a research question
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.